DAYVIGO
Pronunciation: lem-boe-REX-ant (day-VI-goe)


What it isDual orexin receptor antagonist; insomnia.
Why this oneIt outperformed extended-release zolpidem on late-night sleep maintenance in older adults.
What limits itNext-morning somnolence, and seven hours must remain before waking. CYP3A4-dependent; Schedule IV.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Insomnia | Adults | 5 mg QHS | 5-10 mg QHS | 10 mg QHS |
Renal Undefined
Hepatic Moderate impairment: max 5 mg QHS; severe impairment: not recommended
No more than once per night
Available strengths
Pregnancy No human data; animal toxicity only at high multiples of exposure; registry available
Lactation Transferred into breast milk (low, <2% of maternal dose); monitor infant for excessive sedation
| Strength | #/mo | generic $/mo | brand $/mo | CostPlus | |
|---|---|---|---|---|---|
| 5 mg | tab | 30 qd | — | $347.33 | not offered |
| 10 mg | tab | 30 qd | — | $347.01 | not offered |
Generic entry2035 est.
NO BOXED WARNINGS
Principal riskNext-morning somnolence; allow seven hours
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilityNext-day somnolence, abnormal sleep behaviors and additive CNS depression.
Open Lemborexant in the interactive console ↗
